Scarica l'app Stockscreener
108.73
3.73%
3.91
Dopo l'orario di chiusura:
108.73
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$104.82
Aprire:
$102.6
Volume 24 ore:
104.86K
Relative Volume:
1.00
Capitalizzazione di mercato:
$2.09B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
43.32
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
+0.59%
1M Prestazione:
-11.04%
6M Prestazione:
+8.78%
1 anno Prestazione:
+48.52%
Intervallo 1D:
$102.60
$108.77
Intervallo di 1 settimana:
$102.50
$112.49
Portata 52W:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
108.73 | 2.09B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
LGND: First Steps into Cell & Gene Therapy - Research Tree
Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan
Ligand to Participate in March Investor Conferences - Yahoo Finance
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Ligand: Q4 Earnings Snapshot - mySA
Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com
Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com
Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq
LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq
Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com
Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq
Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):